Cargando…
667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost?
BACKGROUND: Pathogen testing using next-generation sequencing of microbial cell-free DNA (NGS cfDNA) is a promising diagnostic tool to identify pathogens that might not be detected using conventional lab evaluation. Considering the cost of this test, it is important to determine when it is most usef...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644926/ http://dx.doi.org/10.1093/ofid/ofab466.864 |
_version_ | 1784610199373348864 |
---|---|
author | Quick, Rachel Downey Martinez, Kelli A Russo, Susan M McGwier, Sarah E Quirt, Rachel A Hauger, Sarmistha Bhaduri Fernandez, Mariosl Murphey, Donald |
author_facet | Quick, Rachel Downey Martinez, Kelli A Russo, Susan M McGwier, Sarah E Quirt, Rachel A Hauger, Sarmistha Bhaduri Fernandez, Mariosl Murphey, Donald |
author_sort | Quick, Rachel Downey |
collection | PubMed |
description | BACKGROUND: Pathogen testing using next-generation sequencing of microbial cell-free DNA (NGS cfDNA) is a promising diagnostic tool to identify pathogens that might not be detected using conventional lab evaluation. Considering the cost of this test, it is important to determine when it is most useful to the plan of care (POC). Figure 1. Unit of admission among cases [Image: see text] Figure 2. Patient characteristics in cases determined to be valuable and not valuable to the plan of care (POC) [Image: see text] METHODS: In this retrospective study, we collected data from the medical charts of 50 consecutive NGS cfDNA tests in a free-standing children’s hospital. We evaluated patients for demographics, underlying conditions, diagnosis at time of testing, conventional laboratory testing and timing, medical treatment, and NGS cfDNA test results for clinical relevance or false negative results compared to conventional testing. The primary goal was to identify patients for whom the NGS cfDNA testing affected the POC. Charts were reviewed, and determinations regarding whether the result influenced the POC were confirmed by a provider. RESULTS: We were unable to differentiate patients with clinically valuable NGS cfDNA results (Fig 1 & 2). Among those with NGS cfDNA results valuable to the POC (n=22), both negative and positive testing guided POC (13 valuable negative vs. 9 diagnostic cases). In the total sample, 5 cases (10%) had a clinically relevant pathogen identified through conventional testing, but not through NGS cfDNA and 2 cases had antimicrobial resistance on culture, which is not detected by NGS cfDNA. CONCLUSION: While we did not find a specific clinical profile for NGS cfDNA use, positive results were essential to the diagnosis in 18% of cases with otherwise negative laboratory evaluation for the pathogen identified in NGS cfDNA. Negative tests affected the POC in 26% of cases by avoiding unnecessary antimicrobials in high risk immunocompromised patients and patients that presented with low-risk of infection, but unclear disease process. Caution must be exercised with reliance on this test with respect to antimicrobial resistance and risk of false negative results. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-8644926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86449262021-12-06 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost? Quick, Rachel Downey Martinez, Kelli A Russo, Susan M McGwier, Sarah E Quirt, Rachel A Hauger, Sarmistha Bhaduri Fernandez, Mariosl Murphey, Donald Open Forum Infect Dis Poster Abstracts BACKGROUND: Pathogen testing using next-generation sequencing of microbial cell-free DNA (NGS cfDNA) is a promising diagnostic tool to identify pathogens that might not be detected using conventional lab evaluation. Considering the cost of this test, it is important to determine when it is most useful to the plan of care (POC). Figure 1. Unit of admission among cases [Image: see text] Figure 2. Patient characteristics in cases determined to be valuable and not valuable to the plan of care (POC) [Image: see text] METHODS: In this retrospective study, we collected data from the medical charts of 50 consecutive NGS cfDNA tests in a free-standing children’s hospital. We evaluated patients for demographics, underlying conditions, diagnosis at time of testing, conventional laboratory testing and timing, medical treatment, and NGS cfDNA test results for clinical relevance or false negative results compared to conventional testing. The primary goal was to identify patients for whom the NGS cfDNA testing affected the POC. Charts were reviewed, and determinations regarding whether the result influenced the POC were confirmed by a provider. RESULTS: We were unable to differentiate patients with clinically valuable NGS cfDNA results (Fig 1 & 2). Among those with NGS cfDNA results valuable to the POC (n=22), both negative and positive testing guided POC (13 valuable negative vs. 9 diagnostic cases). In the total sample, 5 cases (10%) had a clinically relevant pathogen identified through conventional testing, but not through NGS cfDNA and 2 cases had antimicrobial resistance on culture, which is not detected by NGS cfDNA. CONCLUSION: While we did not find a specific clinical profile for NGS cfDNA use, positive results were essential to the diagnosis in 18% of cases with otherwise negative laboratory evaluation for the pathogen identified in NGS cfDNA. Negative tests affected the POC in 26% of cases by avoiding unnecessary antimicrobials in high risk immunocompromised patients and patients that presented with low-risk of infection, but unclear disease process. Caution must be exercised with reliance on this test with respect to antimicrobial resistance and risk of false negative results. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2021-12-04 /pmc/articles/PMC8644926/ http://dx.doi.org/10.1093/ofid/ofab466.864 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Poster Abstracts Quick, Rachel Downey Martinez, Kelli A Russo, Susan M McGwier, Sarah E Quirt, Rachel A Hauger, Sarmistha Bhaduri Fernandez, Mariosl Murphey, Donald 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost? |
title | 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost? |
title_full | 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost? |
title_fullStr | 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost? |
title_full_unstemmed | 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost? |
title_short | 667. Next Generation Sequencing of Microbial Cell Free DNA in the Diagnosis and Treatment of Infectious Disease in Children: When Does the Result Justify the Cost? |
title_sort | 667. next generation sequencing of microbial cell free dna in the diagnosis and treatment of infectious disease in children: when does the result justify the cost? |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644926/ http://dx.doi.org/10.1093/ofid/ofab466.864 |
work_keys_str_mv | AT quickracheldowney 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost AT martinezkellia 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost AT russosusanm 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost AT mcgwiersarahe 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost AT quirtrachela 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost AT haugersarmisthabhaduri 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost AT fernandezmariosl 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost AT murpheydonald 667nextgenerationsequencingofmicrobialcellfreednainthediagnosisandtreatmentofinfectiousdiseaseinchildrenwhendoestheresultjustifythecost |